C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

Type 1 diabetes is associated with such complications as blindness, kidney failure, and nerve damage. Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications. Interestingly, after nearly 30 years of positive research results, C-peptid...

Full description

Saved in:
Bibliographic Details
Published in:Molecular bioSystems 2017-07, Vol.13 (8), p.1432-1437
Main Authors: Pinger, C. W, Entwistle, K. E, Bell, T. M, Liu, Y, Spence, D. M
Format: Article
Language:English
Subjects:
Animals
Bibliometrics
C-Peptide - deficiency
C-Peptide - history
C-Peptide - pharmacokinetics
C-Peptide - therapeutic use
Clinical Trials as Topic
Diabetes Complications - history
Diabetes Complications - metabolism
Diabetes Complications - pathology
Diabetes Complications - therapy
Diabetes Mellitus, Type 1 - history
Diabetes Mellitus, Type 1 - metabolism
Diabetes Mellitus, Type 1 - pathology
Diabetes Mellitus, Type 1 - therapy
Disease Models, Animal
History, 20th Century
History, 21st Century
Humans
Insulin - deficiency
Insulin - history
Insulin - therapeutic use
Insulin-Secreting Cells - metabolism
Insulin-Secreting Cells - pathology
Iron - metabolism
Protein Binding
Serum Albumin - metabolism
Serum Albumin - pharmacokinetics
Zinc - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 1 diabetes is associated with such complications as blindness, kidney failure, and nerve damage. Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications. Interestingly, after nearly 30 years of positive research results, C-peptide is still not being co-administered with insulin to diabetic patients. The following review discusses the potential of C-peptide as an auxilliary replacement therapy and why it's not currently being used as a therapeutic. C-Peptide has been discussed as a missing component in therapy for people with Type 1 diabetes. Is momentum fading, or do technology models suggest that it is right on schedule?
ISSN:1742-206X
1742-2051
DOI:10.1039/c7mb00199a